Update on Investigational Alzheimer's Drug

JULY 01, 2007
Susan Farley

Voyager Pharmaceutical Corp recently informed its shareholders of preliminary results from a trial of an investigational drug to treat Alzheimer's disease (AD). The researchers studying the drug, Memryte, observed positive effects among women but not among men.

The findings have prompted Voyager to focus on developing the drug to treat AD specifically for women.



SHARE THIS SHARE THIS
0

Become A RESPIMAT T.O.P. Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?


Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.